AFTER-HOURS TRADING - Breaking News...%CUSTOM_MINE

[Billie Francis]

AFTER-HOURS TRADING - BREAKING NEWS

Get Quote - http://quote.money.cnn.com/quote/quote?symbols=htds

Hard to Treat Diseases Incorporated - HTDS - Announces: Receipt of Tubercin 
Toxicity Study and Formation of Scientific Advisory Panel - Wednesday December 
3, 8:04 pm ET

DELRAY BEACH, Fla.--(BUSINESS WIRE)--Dec. 3, 2003--Hard to Treat Diseases 
Incorporated (Pink Sheets: HTDS) announces today that the spokesperson for the 
independent medical group conducting the testing for HTTD (HTDS) has forwarded 
the formal Testing Results of Tubercin®'s Toxicity Trials to HTTD.

Tubercin of five different concentrations was administered to five groups of 
mice. A pathologist at the University of Oklahoma Health Science Center 
performed autopsies. The mice were randomized and only the control mouse was 
known to the pathologist, as stated in the cover letter of the Pathology Report.

The report concludes, "All tissues evaluated, visceral organs and the brain 
were essentially normal in appearance." "The importance of this report is even 
better than I expected," stated the spokesperson for the medical group. "As the 
testing continues and if the results are similar to those of Chemotherapy and 
or radiation with no harmful side effects, Tubercin has enormous potential for 
the treatment of cancer and the immune system."

The President and CEO of HTTD, Mr. Colm J. King is in the process of forming a 
Scientific Advisory Panel with leading Oncologists and Immunologists from 
prestigious institutions in the U.S. The panel will review the reports and 
results of Tubercin®'s findings and will report back to Mr. King with the 
ongoing reports in layman language for the shareholders.

"We are continuing to receive promising results regarding Tubercin® and we're 
looking forward to additional positive results in the near future," stated Mr. 
King. "These tests prove that Tubercin® is non-toxic and is the first step on 
the way to human clinical trials as well as the first positive breakthrough 
conducted in the United States with an independent medical group for Tubercin®.

Operating out of Delray Beach, Florida, Hard to Treat Diseases Incorporated 
("HTTD") holds the international marketing rights, except South Korea, to 
Tubercin®, a patented immunostimulant developed for combating Cancer under 
medical patent (US Patent 6,274,356). The unique properties unlike other cancer 
products are clearly stated in the abstract summary of the patent... "A 
carbohydrate complex, which is a mixture of low molecular-weight 
polysaccharides of an arabinomannan structure extracted from Mycobacterium 
tuberculosis, is highly effective in treating various cancer patients without 
incurring any adverse side effects."






Statements in this press release that are not historical facts are 
forward-looking statements within the meaning of the Securities Act of 1933, as 
amended. Those statements include statements regarding the intent, belief or 
current expectations of the Company and its management. Such statements reflect 
management's current views, are based on certain assumptions and involve risks 
and uncertainties. Actual results, events, or performance may differ materially 
from the above forward-looking statements due to a number of important factors, 
and will be dependent upon a variety of factors, including, but not limited to, 
our ability to obtain additional financing and access funds from our existing 
financing arrangements that will allow us to continue our current and future 
operations and whether demand for our product and testing service in domestic 
and international markets will continue to expand. The Company undertakes no 
obligation to publicly update these forward-looking statements to reflect 
events or circumstances that occur after the date hereof or to reflect any 
change in the Company's expectations with regard to these forward-looking 
statements or the occurrence of unanticipated events.



























b  rgpvowtkeu bzregpk b ph
tofzuqga gehmscxgpzffxv
 bj
 e
rsvyypv